Condition: Locally Advanced Solid Tumor · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
This description comes directly from the study's public registry record.
Sujie Zhang · 86-13811303576 · sujie.zhang@innoventbio.com
Yue Qu · 86-18664524992 · yue.qu@innoventbio.com
Always discuss trial participation with your own doctor first.
| Wollongong Public | Wollongong, New South Wales, Australia | Recruiting |
| Cancer Research SA | Adelaide, South Australia, Australia | Recruiting |
| Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital of zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06349408